Q-omics provides the consensus-scored ZNF652 profile across patient tissues and cancer cell-line models. ZNF652 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF652 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNF652 RNA expression shows 21,832 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, THCA, and ACC as cancer lineages where ZNF652 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF652 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF652 survival associations across molecular data types. ZNF652 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF652 RNA expression–survival associations across cancer types. High ZNF652 expression shows unfavorable associations in ACC, KIRP and KICH, but favorable associations in BRCA, HNSC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF652 RNA expression.
This table summarizes ZNF652 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF652. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF652 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BRCA and CHOL. The THCA box plot shows higher ZNF652 RNA expression in normal versus tumor tissue (log2 FC = −1.012, t-test p < 0.001).
This table shows molecular features associated with ZNF652 in patient tissues and cancer cell lines. In patient samples, ZNF652 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF652 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
